Methylphenidate en es it fr

Methylphenidate Brand names, Methylphenidate Analogs

Methylphenidate Brand Names Mixture

  • No information avaliable

Methylphenidate Chemical_Formula


Methylphenidate RX_link

Methylphenidate fda sheet

Methylphenidate FDA

Methylphenidate msds (material safety sheet)

Methylphenidate MSDS

Methylphenidate Synthesis Reference

M. Hartmann, L. Panizzon, U.S. Pat. 2,507,631 (1950)

Methylphenidate Molecular Weight

233.306 g/mol

Methylphenidate Melting Point


Methylphenidate H2O Solubility


Methylphenidate State


Methylphenidate LogP


Methylphenidate Dosage Forms

Tablets; Tablets (sustained release)

Methylphenidate Indication

For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.

Methylphenidate Pharmacology

Methylphenidate is a central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of dextroamphetamine.

Methylphenidate Absorption

Readily absorbed in a biphasic manner. It reaches peak absorption at approximately two hours for the first phase and five hours for the second phase. Bioavailability is low (approximately 30%)

Methylphenidate side effects and Toxicity

Symptoms of overdose include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes. LD50=190mg/kg (orally in mice)

Methylphenidate Patient Information

Methylphenidate Organisms Affected

Humans and other mammals